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Assessment of Hepatocellular Carcinoma
Vascularity: Comparison of Contrast-
enhanced Coded Harmonic Ultrasound with
Harmonic Power Doppler Ultrasound
Jae-Young Lee, Byung-Ihn Choi, Ah-Young Kim,1 Joon-Koo Han,
Shang-Hun Shin and Chang-Min Park
Background: The aim of this study was to evaluate contrast-enhanced coded
harmonic ultrasound (CHUS) in the depiction of the vascularity of hypervascular
hepatocellular carcinomas (HCCs) by comparing it with that of contrast-enhanced
harmonic power Doppler ultrasound (HPDUS).
Materials and Methods: Contrast-enhanced CHUS was prospectively performed
in 17 consecutively collected hypervascular HCCs (mean diameter, 3.4 cm; range,
1.8–7.8 cm) using the Coded Harmonic Angio mode of a LOGIQ 700 Expert unit
and a 2 to 4 MHz curved linear-array probe. This was conducted using a microbubble
contrast agent (Levovist·) and interval-delay scanning (scan interval, 20–30 s;
scanning time, 2–5 s). All patients also underwent contrast-enhanced HPDUS, and
the results were compared in terms of the depiction and degree of enhancement
of tumor vascularity (feeding vessels, intratumoral macrovessels, intratumoral
microvessels, and tumor staining), and the presence of artifacts.
Results: There was no significant difference between CHUS and HPDUS in
depiction of tumor vascularity in terms of feeding vessels, intratumoral macrovessels
and intratumoral microvessels. CHUS, however, was superior to HPDUS in terms
of tumor staining (p = 0.008). The degree of tumor vascularity enhancement was
superior with CHUS in depicting tumor staining (p = 0.001), but HPDUS was better
in depicting intratumoral macrovessels (p = 0.039). CHUS was artifact-free, while
several artifacts were seen in all HCCs examined with HPDUS.
Conclusions: Our results suggest that CHUS is capable of depicting tumor
vascularity of hypervascular HCCs and is superior to HPDUS. Contrast-enhanced
CHUS may be useful, therefore, in evaluating tumor vascularity of HCCs.
(J Med Ultrasound 2003;11:147–55)
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INTRODUCTION
Hepatocellular carcinoma (HCC) is typically a very
hypervascular tumor. Demonstration of vascularity
is necessary for the diagnosis of HCC, choice of
treatment method, and the assessment of therapeutic
response after non-surgical treatment, such as
chemotherapeutic embolization, percutaneous ethanol
injection therapy, and radiofrequency (RF) ablation.
The value of conventional Doppler ultrasound
(US) in demonstrating the vascularity of HCC has
been described by many investigators [1–6]. Since
microbubble contrast agents for US have become
available, many researchers have reported the useful-
ness of contrast-enhanced Doppler US in demon-
strating tumor vascularity of hepatic tumors [7–16].
Kim et al reported that contrast-enhanced power
Doppler US was superior to unenhanced power Dop-
pler US in the demonstration and characterization
of tumor vascularity in HCC [8]. Furthermore, the
high diagnostic agreement of contrast-enhanced pow-
er Doppler US with contrast-enhanced computed
tomography (CT) suggested it as an alternative to
immediate follow-up CT for the evaluation of the
therapeutic effect after treatment of HCCs with
RF ablation [17]. However, contrast-enhanced power
Doppler US is highly susceptible to tissue motion
artifact, which limits the use of this technique in
patients with hepatic masses near the heart or the
great vessels [8]. By combining it with harmonic
technique, contrast-enhanced power Doppler US has
been shown to be more effective in evaluating tu-
mor vascularity of HCCs because harmonic power
Doppler US (HPDUS) generates fewer power Dop-
pler artifacts [14]. Nevertheless, this limitation was
thought to have been overcome after the advent of
the gray-scale harmonic US technique. According
to some early reports of gray-scale US, contrast-
enhanced gray-scale harmonic US imaging appeared
superior to unenhanced conventional Doppler US
for the characterization of hepatic tumors [13].
Moreover, tumor vascularity of HCCs was success-
fully demonstrated by using contrast-enhanced
pulse-inversion harmonic US [16].
Recently, coded harmonic US (CHUS) has been
introduced as a new real-time gray-scale second
harmonic US imaging technique, and the system is
equipped with the recently developed coded excitation
mode (Coded Harmonic Angio, GE Medical Systems,
Milwaukee, WI, USA). In a recent study of CHUS,
it was suggested that contrast-enhanced CHUS could
depict tumor vascularity and tumor parenchymal
flow with increased sensitivity and specificity in
evaluating post-treatment response of HCCs treated
with chemotherapeutic embolization, even when
compared with dynamic contrast-enhanced CT [18].
It was also suggested that contrast-enhanced CHUS
was comparable to magnetic resonance imaging in
its ability to show peripheral nodular enhancement
with centripetal progression, even in small heman-
giomas [19]. However, to our knowledge, there
has been no report comparing contrast-enhanced
CHUS with contrast-enhanced Doppler US.
This study was carried out, therefore, to determine
the ability of contrast-enhanced CHUS to depict
vascularity in HCCs by comparing it with that of
contrast-enhanced HPDUS.
MATERIALS AND METHODS
Subjects
From June to July 2000, 17 patients with clinically
or histopathologically diagnosed hypervascular HCC
were evaluated with contrast-enhanced CHUS. All
patients gave fully informed consent for the study,
which had been approved by our institutional review
board.
There were 13 men and four women (mean age,
57 years; range, 39–81 years). Six patients had histo-
logic confirmation of HCC: one from a percuta-
neous biopsy and five from surgery. A clinical diag-
nosis had been made in the remaining 11 patients
from the results of hepatic angiography or CT
and an _-fetoprotein level > 500 ng/mL. Tumor
diameter on US was as follows: less than 3 cm
(n = 9), 3 to 5 cm (n = 5), and more than 5 cm
(n = 3). The mean diameter of the 17 HCCs was
3.4 cm (range, 1.8–7.8 cm).
Imaging methods
The contrast agent used was SH U 508 A (Levovist·;
Schering, Berlin, Germany); it is a suspension of
monosaccharide microparticles (galactose) in ster-
ile water. The agent was prepared for injection by
shaking it with 11 mL of water for 5 to 10 seconds.
After standing for 2 minutes for equilibration,
6.5 mL of the suspension (concentration 300 mg/mL)
was injected manually through a 20 to 22 gauge
cannula (Cath-S; Boin Medica, Seoul, South Korea)
placed in an antecubital vein. This was followed by
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3 to 5 mL of physiologic saline to flush the cannula
at the same injection rate. Bolus injection techniques
were used, and injections given at a rate of ap-
proximately 0.5 mL/second for both CHUS and
HPDUS.
US was performed by one radiologist using a
LOGIQ 700 Expert unit (GE Medical Systems) and
a 2 to 4 MHz curved linear-array probe. The acous-
tic power of CHUS was set at the default (maxi-
mum) setting. When performing HPDUS, the pulse
repetition frequency was set at a constant 1,700 Hz
in all patients. The color gain was manipulated un-
til color noise first became apparent in the region
of interest of the image background. The resultant
power Doppler US gains ranged from 51% to
61% for HPDUS. The color-write priority was set
at the maximum.
For CHUS, we chose a scanning plane that
included the tumor before injection of the contrast
agent. Sector width was manipulated to as narrow
as possible to minimize the disruption of micro-
bubbles out of the region of interest. With these pre-
determined settings, we obtained the first series of
CHUS images 20 to 30 seconds after the first bolus
injection of contrast agent. We then obtained each
series of CHUS images by interval-delay scanning
at intervals of 10 to 20 seconds until contrast agent
signals had completely disappeared from within the
tumor. We also waited until the contrast agent signals
completely disappeared from within the liver. Serial
contrast-enhanced HPDUS was then performed using
interval-delay scanning at intervals of 10 to 20
seconds, beginning from 20 to 30 seconds after the
bolus injection of contrast agent. The scanning time
during interval-delay scanning was 2 to 5 seconds
for both CHUS and HPDUS. All images obtained
by both techniques were recorded on videotape and
stored in the hardware of the imaging unit. Reviewing
cine loop images, one or two static images depicting
tumor vascularity were stored in the hardware be-
tween each scanning time.
Two-phase spiral CT examinations were per-
formed using various spiral CT scanners to obtain
a diagnosis of hypervascular HCC. Each patient
received 120 mL of non-ionic contrast material –
iopromide (Ultravist 370·; Schering) – intravenously
at a rate of 3 mL/second. Hepatic arterial phase and
portal venous phase scans were obtained 30 and 65
seconds, respectively, after the first injection of
contrast material.
Analysis
To enable comparison of CHUS and HPDUS in
terms of tumor vascularity depiction, vascularity
was categorized into four types: feeding vessel, in-
tratumoral macrovessel, intratumoral microvessel,
and tumor staining (Fig. 1). Feeding vessels were
defined as peritumoral vessels that supplied a tumor.
Intratumoral macrovessels were defined as in-
tratumoral vessels that were the first or second or-
der branch of a feeding vessel, and vessels that were
smaller than intratumoral macrovessels were classi-
fied as intratumoral microvessels. Tumor staining
was defined as diffuse contrast enhancement with-
out definable vascular structure. Intratumoral
macrovessels were subdivided into branching and
linear types according to the presence or absence
of a branching pattern of macrovascular signals.
Intratumoral microvessels were subdivided into
branching, reticular, and spotty types according to
their predominant feature. Tumor staining was
subdivided into diffuse, central, peripheral, and
multifocal types according to what was predominant.
The time when each type of tumor vascularity was
optimally depicted (optimal depiction time) was
recorded.
To compare the degree of enhancement of tumor
vascularity, the CHUS and HPDUS images that best
depicted each type of tumor vascularity were selected
Fig. 1. Types of tumor vascularity. A = feeding vessel;
B = intratumoral macrovessel (branching type); C =
intratumoral macrovessel (linear type); D = intratumoral
microvessel (branching type); E = intratumoral microvessel
(reticular type); F = intratumoral microvessel (spotty
type); G = tumor staining.
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and compared in terms of the number and extent
of each type. In addition, the frequency of artifact
occurrence in both US techniques was compared.
US signals that were observed inconsistently outside
the vascular structure were regarded as artifacts.
Image analysis was conducted using the static
images obtained on CHUS and HPDUS, and a
consensus arrived at by three abdominal radiolo-
gists. Statistical comparison was performed using
the McNemar Chi-squared test and Wilcoxon signed
rank test. A p value of less than 0.05 indicated a
statistically significant difference.
RESULTS
Table 1 shows a comparison of tumor vascularity
depiction between CHUS and HPDUS. Feeding
vessels were demonstrated in 14 of 17 HCCs
(82%) with both CHUS and HPDUS. Intratumoral
macrovessels were depicted in 15 of 17 HCCs
(88%) with both CHUS and HPDUS. However, the
branching type of macrovessel was more frequently
depicted with CHUS than with HPDUS, although
this was not statistically significant (p = 0.289). In-
tratumoral microvessels were demonstrated in nine
of 17 HCCs (53%) with CHUS and 10 of 17 HCCs
(59%) with HPDUS (p = 1.000). CHUS showed mi-
crovessels of either the branching or the reticular
type in eight HCCs, while HPDUS revealed the
spotty type in all 10 HCCs (p < 0.05) (Fig. 2). In
tumor staining, CHUS demonstrated various pat-
terns in 12 of 17 HCCs (71%), while HPDUS did
so in only four of 17 HCCs (24%) (p < 0.05).
The optimal depiction times for each type of
tumor vascularity, using CHUS and HPDUS, are
shown in Table 2. Neither CHUS nor HPDUS showed
a significant difference in optimal depiction time of
tumor vasculature (p > 0.05).
A comparison of the degree of enhancement
between CHUS and HPDUS (Table 3) showed that
CHUS was superior to HPDUS in depicting tumor
staining (p < 0.05), while HPDUS was superior to
CHUS in depicting intratumoral macrovessels (p <
0.05).
US artifacts were not seen on any CHUS images.
However, two types of artifact signals were seen to
a variable degree in all HCCs with HPDUS (Figs.
2–4). The first type of power Doppler artifact ap-
peared to be diffuse (Fig. 2), linear, or spotty (Fig.
3), and resembled tumor staining, macrovessel or
microvessel, respectively. In all four HCCs that
occurred in the left hepatic lobe, artifacts were de-
tected on HPDUS because of the effects of respi-
ration and heart movement. In the second type of
Table 1. Comparison of tumor vascularity depiction between coded harmonic US (CHUS) and harmonic
power Doppler US (HPDUS) in 17 hepatocellular carcinomas
CHUS HPDUS p*
n (%) n (%)
Feeding vessel 14 (82) 14 (82) 1.000
Macrovessel 15 (88) 15 (88) 1.000
   Branching 7 3 0.289
   Linear 8 12 0.289
Microvessel 9 (53) 10 (59) 1.000
   Branching 5 0 0.063
   Reticular 3 0 0.250
   Spotty 1 10 0.004
Tumor staining 12 (71) 4 (24) 0.008
   Diffuse 7 3
   Central 1 0
   Peripheral 1 0
   Multifocal 3 1
*McNemar Chi-squared test.
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Fig. 2. A 3 cm hepatocellular carcinoma
in the right hepatic lobe of a 63-year-
old man. (A) Coded harmonic US
images. The image obtained before
injection of the contrast agent, at 0
seconds, shows a slightly hypoechoic
mass. The images obtained at 31 seconds
and 50 seconds after injection show
feeding vessels (arrowheads) and
intratumoral microvessels of branching
(arrow) and reticular (open arrow)
types. Diffuse tumor staining is seen 93
seconds after injection. (B) Harmonic
power Doppler US images. The image
obtained at 27 seconds after injection
shows feeding vessels (arrowheads) and
linear type of intratumoral macrovessels
(arrows). A spotty intratumoral mi-
crovessel is demonstrated in the image
obtained at 63 seconds after injection.
Diffuse tumor staining appears in the
image obtained at 192 seconds after
injection. However, parenchymal
staining (open arrow) also appears in
the adjacent liver. This can make iden-
tification of true tumor staining from
diffuse signals in the tumor difficult.
Artifacts induced by respiration and
heart motion were also observed (not
shown).
B
A
artifact, blooming artifacts began to appear at a
range of 90 to 99 seconds post-injection (mean,
92 s) (Fig. 3). Three of four HCCs showing tumor
staining with HPDUS showed blooming artifacts
around the tumor. These artifacts caused deteriora-
tion of tumor conspicuity and vascularity.
DISCUSSION
CHUS has been introduced recently as a new gray-
scale second harmonic US imaging technique em-
ploying contrast agents based on digitally encoded
ultrasound technology [19]. CHUS uses a special
code sequence to tag the fundamental transmit fre-
quency band. When this coded pulse is transmitted
into the body, a second harmonic frequency band is
generated inside the body; the decoder processes the
total received signal to identify the tagged fun-
damental frequency band and then removes it without
affecting the second harmonic frequency band. From
these received harmonic signals, any signals from
large and slow-moving tissue-clutter components are
subtracted by a specialized decoding technique. This
filter mechanism makes it possible to effectively
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suppress any stationary tissue-clutter component
relative to any moving microbubble or blood echo
component among the harmonic signals. The CHUS
technique, therefore, has the potential to provide
high sensitivity to contrast-agent echo by high con-
trast resolution, as well as preservation of wide-
band resolution of harmonic signals.
As expected, our results showed that these
advantages enabled CHUS to depict tumor vascu-
larity as well as or even better than HPDUS. In
addition, branching and reticular types of intra-
tumoral microvessels were detected only with
CHUS, while the spotty type was mostly found with
HPDUS. It might be said that CHUS can provide
more detailed intratumoral vascular information on
HCCs than HPDUS, although verification of this
suggestion would require further study.
In this study, we used an easily breakable mi-
crobubble contrast agent. Nevertheless, our results
indicate that CHUS is potentially useful for detailed
evaluation of tumor vascularity. It is expected that
this ability of CHUS to assess tumor vascularity will
be very useful in determining the presence of resid-
ual viable tumor after local treatment for malignant
tumor as well as in characterizing hepatic tumors.
With contrast-enhanced power Doppler US, exact
evaluation of the intratumoral vasculature is difficult
because of a considerable blooming artifact produced
during the early phase of contrast agent enhancement
[8]. Furthermore, its susceptibility to tissue motion
limits the use of this technique in patients who have
difficulty in breath-holding and in patients with
hepatic masses near the heart or great vessels [8,
20]. Another limitation of power Doppler US is that
the size or extent of a vasculature within a lesion
can be overestimated [21]. Contrast-enhanced
HPDUS has similar limitations, although HPDUS
is known to generate less power Doppler or bloom-
ing artifacts when compared with conventional pow-
er Doppler US [14]. In contrast, use of CHUS
overcomes these problematic artifacts, as our results
show. CHUS can thus be used with lesions near the
Table 2. Comparison of the optimal depiction times between coded harmonic US (CHUS) and harmonic
power Doppler US (HPDUS) in 17 hepatocellular carcinomas
Mean (range) optimal depiction time, s
CHUS HPDUS p*
Feeding vessel 43 (20–67) 41 (20–86) > 0.05
Macrovessel 47 (21–115) 42 (20–86) > 0.05
Microvessel 57 (30–118) 62 (21–146) > 0.05
Tumor staining 59 (21–119) 98 (33–192) > 0.05
*Wilcoxon signed rank test.
Table 3. Comparison of the degree of enhancement between coded harmonic US (CHUS) and harmonic
power Doppler US (HPDUS) in 17 hepatocellular carcinomas
CHUS > HPDUS CHUS = HPDUS HPDUS > CHUS p*
Feeding vessel 3 8 3 1.000
Macrovessel 1 7 8 0.039
Microvessel 9 1 2 0.065
Tumor staining 11 1 0 0.001
*McNemar Chi-squared test. Data are presented as the number of cases.
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Fig. 3. A 2.7 cm hepatocellular carcinoma
in the right hepatic lobe of a 51-year-old
woman. (A) Coded harmonic US images.
Feeding vessels (arrows) are demonstrated
in the image at 35 seconds after injection
of contrast agent. A branching type of
intratumoral macrovessel (arrow) is well
visualized on the image obtained at 39
seconds after injection; reticular type of in-
tratumoral microvessels (open arrows) are
also depicted within the tumor. The tumor
is diffusely stained on the images obtained
at 40 and 64 seconds after injection.
(B) Harmonic power Doppler US images.
Feeding vessels (arrows) surrounding the
tumor were seen 30 seconds after contrast-
agent injection. At 32 seconds, spotty signals
(arrows) from the diffusely stained tumor
are seen. Such signals can cause confusion
due to the similarity in appearance to
intratumoral spotty microvessel signals.
Intratumoral spotty microvessel signals
(open arrows) are seen on the images at
70 and 96 seconds after injection of contrast
agent. A blooming artifact (black arrow)
around the portal vein is noted on the
image obtained at 96 seconds.
A
B
heart or great vessels. CHUS, however, has the dis-
advantage that its imaging resolution is considered
inferior to conventional gray-scale imaging. This is
because CHUS suppresses both the fundamental and
harmonic signals from the stationary background
tissue. Due to this disadvantage, CHUS sometimes
obscures the contour of deep-seated lesions and its
use is, thus, limited in these lesions.
This study had several limitations. First, most of
the HCCs were not pathologically proven and, there-
fore, their tumor vascularity could not be patholo-
gically correlated. Second, there was no gold standard
of imaging method available to compare tumor
vascularity with CHUS and HPDUS. This meant that
we could not obtain diagnostic values from CHUS,
but only indicate the ability of CHUS to detect each
type of tumor vascularity. Third, we did not evaluate
whether CHUS could demonstrate serial contrast-
enhancement change in HCCs during the hepatic
arterial and portal venous phases; this study focused
only on the comparison of two techniques for
detecting tumor vascularity.
Despite these limitations, our results suggest
that CHUS can adequately depict vascularity of hyper-
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vascular HCCs, and is superior in this respect to
HPDUS. Contrast-enhanced CHUS, therefore, may
offer potential in illustrating HCC vascularity.
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